Chemistry:RG7795
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Other names | RG-7795; ANA773; ANA-773 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C12H14N4O5S |
| Molar mass | 326.33 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
RG7795 (previously ANA773) is an antiviral drug candidate that as of 2015 had been in Phase II trials in hepatitis B.[1] It is an orally-available prodrug of isatoribine,[2] that was under development by Anadys Pharmaceuticals when it was acquired by Roche in 2011.[3] Its active metabolite is an agonist of TLR7; activation of TLR7 causes secretion of endogenous type 1 interferons, which have antiviral activity.[2]
As of 2021, development of RG7795 appears to be discontinued.[4]
References
- ↑ "RG 7795" (in en). AdisInsight. Springer Nature Switzerland AG. http://adisinsight.springer.com/drugs/800023738.
- ↑ Jump up to: 2.0 2.1 "Tickling the TLR7 to cure viral hepatitis". Journal of Translational Medicine 12: 129. May 2014. doi:10.1186/1479-5876-12-129. PMID 24884741.
- ↑ "Inovio Goes It Alone on Hepatitis B Immunotherapy Vaccine as Roche Ends Collaboration". Genetic Engineering News. August 3, 2016. http://www.genengnews.com/gen-news-highlights/inovio-goes-it-alone-on-hepatitis-b-immunotherapy-vaccine-as-roche-ends-collaboration/81253045.
- ↑ Sachin Bhagchandani, Jeremiah A.Johnson, and Darrell J.Irvine (2021). "Evolution of Toll-like receptor 7/8 agonist therapeutics and their delivery approaches: From antiviral formulations to vaccine adjuvants". Advanced Drug Delivery Reviews 175: 113803. doi:10.1016/j.addr.2021.05.013. PMID 34058283.
 |  |
